Michael Y Yang

US Patent:

6552017, Apr 22, 2003

Filed:

Jun 15, 2000

Appl. No.:

09/595250

Inventors:

Albert J. Robichaud - Landenberg PA
Taekyu Lee - Wilmington DE
Wei Deng - Wilmington DE
Ian S. Mitchell - Philadelphia PA
Michael Guang Yang - Wilmington DE
Simon Haydar - Niskayuna NY
Wenting Chen - Exton PA
Christopher D. Mc Clung - Wilmington DE
Emilie J. B. Calvello - Bryn Mawr PA
David M. Zawrotny - Moorestown NJ

Assignee:

Bristol-Myers Squibb Pharma Company - Wilmington DE

International Classification:

C07D48700

US Classification:

514219, 514250, 540494, 540556, 544343

Abstract:

The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R , R , R , R , R , R , R , X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

US Patent:

6632812, Oct 14, 2003

Filed:

Apr 11, 2001

Appl. No.:

09/832455

Inventors:

Qi Han - Hockessin DE
Hong Liu - Glen Mills PA
Richard E. Olson - Wilmington DE
Michael G. Yang - Wilmington DE

Assignee:

Dupont Pharmaceuticals Company - Wilmington DE

International Classification:

C07D24324

US Classification:

514221, 540509

Abstract:

This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to -amyloid production such as Alzheimers disease and Downs Syndrome.

US Patent:

6713476, Mar 30, 2004

Filed:

Apr 3, 2001

Appl. No.:

09/824945

Inventors:

Michael G Yang - Wilmington DE
Hong Liu - Glen Mills PA

Assignee:

Dupont Pharmaceuticals Company - Wilmington DE

International Classification:

C07D22318

US Classification:

514221, 540509

Abstract:

This invention relates to novel lactams having the Formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to -amyloid production such as Alzheimers disease and Downs Syndrome.

US Patent:

6759404, Jul 6, 2004

Filed:

Apr 3, 2001

Appl. No.:

09/825211

Inventors:

Richard E. Olson - Wilmington DE 19803
Michael G. Yang - Wilmington DE 19807

International Classification:

C07D40312

US Classification:

51421103, 540488, 540490, 540491, 540500, 540509, 540523, 540492, 540522, 540524, 540527, 51421104, 51421105, 51421107

Abstract:

Novel cyclic malonamides having the formula (I): and their pharmaceutical compositions. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein.

US Patent:

6900199, May 31, 2005

Filed:

Oct 14, 2003

Appl. No.:

10/685031

Inventors:

Qi Han - Hockessin DE, US
Hong Liu - Glen Mills PA, US
Richard E. Olson - Wilmington DE, US
Michael G. Yang - Wilmington DE, US

Assignee:

Bristol-Myers Squibb Pharma Company - Princeton NJ

International Classification:

C07D243/24
A61K038/00
A61P025/28

US Classification:

51421204, 540522

Abstract:

This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

US Patent:

7001901, Feb 21, 2006

Filed:

Aug 27, 2003

Appl. No.:

10/650358

Inventors:

Michael G. Yang - Narberth PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/55
A61K 31/41
C07D 267/02
C07D 401/12
C07D 257/04

US Classification:

51421709, 514326, 514381, 540491, 540603, 546210, 548252

Abstract:

This invention relates to novel tetrazolyl-propionamides in which the amide group comprises an aminoazepinone, and related structures, of Formula (I):.

US Patent:

7053081, May 30, 2006

Filed:

Dec 24, 2003

Appl. No.:

10/746769

Inventors:

Richard E. Olson - Wilmington DE, US
Michael G. Yang - Wilmington DE, US

Assignee:

Bristol-Myers Squibb Pharma Company - Princeton NJ

International Classification:

A61P 25/28

US Classification:

51421103, 51421104, 51421105, 51421107

Abstract:

This invention relates to novel cyclic malonamides having the formula (I):.

US Patent:

RE39679, Jun 5, 2007

Filed:

Feb 16, 2006

Appl. No.:

11/356423

Inventors:

Albert J. Robichaud - Landenberg PA, US
Taekyu Lee - Wilmington DE, US
Wei Deng - Wilmington DE, US
Ian S. Mitchell - Philadelphia PA, US
Michael Guang Yang - Wilmington DE, US
Simon Haydar - Niskayuna NY, US
Wenting Chen - Exton PA, US
Christopher D. McClung - Wilmington DE, US
Emile J. B. Calvello - Bryn Mawr PA, US
David M. Zawrotny - Moorestown NJ, US
Parthasarathl Rajagopalan - Chennai, IN

Assignee:

Bristol-Myers Squibb Pharma Company - Princeton NJ

International Classification:

C07D 267/22
C07D 281/18
C07D 267/02
C07D 279/00
C07D 265/34

US Classification:

5142111, 514215, 5142245, 514287, 540468, 540546, 544 14, 544 99

Abstract:

The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R, R, R, R, R, R, R, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.